At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
Everolimus +3 moredrug
Likely dose
Everolimus 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma
In Brief
A Phase 2 clinical trial evaluating Everolimus, Tamoxifen, and 2 other interventions for Advanced, Persistent, or Recurrent Endometrial Cancer. Completed, enrolled 74 participants across 26 sites.
Detailed Summary
The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartMay 2015
Primary CompletionJan 2018
Study CompletionAug 2024
TodayJul 2026
First PostedAug 29, 2014
Enrollment StartMay 21, 2015
Primary CompletionJan 1, 2018
Study CompletionAug 22, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.8 years ago
Interventions
Everolimusdrug
10mg daily by mouth
Tamoxifendrug
20 mg daily by mouth on alternating weeks (even numbered) weeks
Letrozoledrug
2.5mg once a day by mouth
Medroxyprogesterone Acetatedrug
200 mg daily by mouth